BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Olejnik J, Hume AJ, Leung DW, Amarasinghe GK, Basler CF, Mühlberger E. Filovirus Strategies to Escape Antiviral Responses. Curr Top Microbiol Immunol 2017;411:293-322. [PMID: 28685291 DOI: 10.1007/82_2017_13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 McElroy AK, Mühlberger E, Muñoz-Fontela C. Immune barriers of Ebola virus infection. Curr Opin Virol 2018;28:152-60. [PMID: 29452995 DOI: 10.1016/j.coviro.2018.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
2 Hume AJ, Mühlberger E. Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family. J Mol Biol 2019;431:4290-320. [PMID: 31260690 DOI: 10.1016/j.jmb.2019.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Diallo I, Ho J, Laffont B, Laugier J, Benmoussa A, Lambert M, Husseini Z, Soule G, Kozak R, Kobinger GP, Provost P. Altered microRNA Transcriptome in Cultured Human Liver Cells upon Infection with Ebola Virus. Int J Mol Sci 2021;22:3792. [PMID: 33917562 DOI: 10.3390/ijms22073792] [Reference Citation Analysis]
4 Edwards MR, Basler CF. Current status of small molecule drug development for Ebola virus and other filoviruses. Curr Opin Virol 2019;35:42-56. [PMID: 31003196 DOI: 10.1016/j.coviro.2019.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
5 Hargreaves A, Brady C, Mellors J, Tipton T, Carroll MW, Longet S. Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. Pathogens 2021;10:1201. [PMID: 34578233 DOI: 10.3390/pathogens10091201] [Reference Citation Analysis]
6 Jain S, Khaiboullina SF, Baranwal M. Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. Pathogens 2020;9:E850. [PMID: 33080902 DOI: 10.3390/pathogens9100850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Hume A, Mühlberger E. Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner. J Infect Dis 2018;218:S403-8. [PMID: 30165526 DOI: 10.1093/infdis/jiy473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Escaffre O, Juelich TL, Freiberg AN. Polyphenylene carboxymethylene (PPCM) in vitro antiviral efficacy against Ebola virus in the context of a sexually transmitted infection. Antiviral Res 2019;170:104567. [PMID: 31351092 DOI: 10.1016/j.antiviral.2019.104567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Olejnik J, Mühlberger E, Hume AJ. Recent advances in marburgvirus research. F1000Res 2019;8:F1000 Faculty Rev-704. [PMID: 31131088 DOI: 10.12688/f1000research.17573.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chanthamontri CK, Jordan DS, Wang W, Wu C, Lin Y, Brett TJ, Gross ML, Leung DW. The Ebola Viral Protein 35 N-Terminus Is a Parallel Tetramer. Biochemistry 2019;58:657-64. [PMID: 30592210 DOI: 10.1021/acs.biochem.8b01154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Woolsey C, Menicucci AR, Cross RW, Luthra P, Agans KN, Borisevich V, Geisbert JB, Mire CE, Fenton KA, Jankeel A, Anand S, Ebihara H, Geisbert TW, Messaoudi I, Basler CF. A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge. Cell Rep 2019;28:3032-3046.e6. [PMID: 31533029 DOI: 10.1016/j.celrep.2019.08.047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
12 Pavlovich SS, Darling T, Hume AJ, Davey RA, Feng F, Mühlberger E, Kepler TB. Egyptian Rousette IFN-ω Subtypes Elicit Distinct Antiviral Effects and Transcriptional Responses in Conspecific Cells. Front Immunol 2020;11:435. [PMID: 32231668 DOI: 10.3389/fimmu.2020.00435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Escudero-Pérez B, Muñoz-Fontela C. Role of Type I Interferons on Filovirus Pathogenesis. Vaccines (Basel) 2019;7:E22. [PMID: 30791589 DOI: 10.3390/vaccines7010022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Basler CF, Krogan NJ, Leung DW, Amarasinghe GK. Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets. Antiviral Res 2019;162:90-100. [PMID: 30550800 DOI: 10.1016/j.antiviral.2018.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
15 Williams CG, Gibbons JS, Keiffer TR, Luthra P, Edwards MR, Basler CF. Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways. J Virol 2020;94:e00191-20. [PMID: 32295912 DOI: 10.1128/JVI.00191-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]